EXPANSION OF INDUSTRIAL BASE FOR BIOLOGICAL VACCINE PROD

File: 970107_sep96_decls49_0002.txt
Page: 0002
Total Pages: 2

Subject: EXPANSION OF INDUSTRIAL BASE FOR BIOLOGICAL VACCINE PROD        

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003201

Folder Title: EXPANSION OF INDUSTRIAL BASE FOR BIOLOGICAL VACCINE - 3                                         

Document Number:          1

Folder Seq  #:         73





                                     UNCLASSIFIED
                                       R rr_ Ur. I
                                        JL-%JI,LL- 1


                 2. Contract with Lederle-Praxis Biologicals of Pearl
       River, New York, to begin production of
       anthrax vaccine by February 15, 1991.

                 3. Establish the appropriate intergovernmental
       arrangements with the National Cancer Institute - Frederick
       Cancer Research Facility at Fort Detrick, Maryland, to begin
       production of                    anthrax vaccine by February 15,
       1991.

                 4. Modify the contract with
       Inc., to produce seratype E and C botulinum toxoid
       doses of serotype E production to be completed bX may 15, iggi.
       Upon completion of the serotype E, production of
       serotype C is to commence.

                 5. Modify the contract with the Michigan Department of
       Public Health to renovate their facility to allow for the
       simultaneous production of multiple serotypes of botulinum toxoid
       by September 1, 1991.

                 6. The U.S. Army Surgeon Generalls office is to
       evaluate by December 15, 1990, the mission priorities of the U.S.
       Army Medical Research institute of Infectious Diseases (USAMRIID)
       at Ft. Detrick, Maryland, to determine if their effort should be
       directed into production of botulinum toxoid. While this
       evaluation is ongoing begin the required renovations, purchase of
       equipment and vaccination of personnel at USAMRIID necessary to
       qualify the facility for production of botulinum toxoid.

                In addition, I request that you task the U.S. Army
       Surgeon General to establish and be the executive manager of an
        mplementation Working Group to expedite these actions. The
        mplementation Working Group should be led by a flag officer.
    @lhe Implementation Working Group should be provided with the
tractual, acquisition, and
       procurement matters.







       Attachments:
       As stated



       cc:
       U.S. Army Surgeon General






                                 UNCLASSIFIED

Document 2 f:/Week-36/BX003201/EXPANSION OF INDUSTRIAL BASE FOR BIOLOGICAL VACCINE - 3/expansion of industrial base for biological vacc:01029715473950
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003201
Unit = OTSG
Parent Organization = HSC
Folder Title = EXPANSION OF INDUSTRIAL BASE FOR BIOLOGICAL VACCINE - 3
Folder Seq # = 73
Subject = EXPANSION OF INDUSTRIAL BASE FOR BIOLOGICAL VACC
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 02-JAN-1997